Novartis and TARGET PharmaSolutions jointly issued a press release touting that Novartis is the first industry partner to provide multi-year support for the development of the TARGET-DERM registry. Published in ClincialTrials.gov, TARGET-DERM is a 5-year, longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies. Skin conditions include Atopic Dermatitis, Alopecia, Hidradenitis Suppurativa, Vitiligo and Psoriasis.
The sponsor is targeting 15,000 participants for this 5-year observational study that is scheduled for completion December 2026. During the study biospecimens will be retained including samples with DNA. Patients enrolled in the TARGET-DERM may be invited to participate in the Biorepository Bank (BSB). Blood, buccal and tape strip samples for biomarker and DNA assays will be collected on a voluntary basis and participation in this project will not affect participation in the main study. These samples will be shipped to a central repository for storage to use in future studies. Samples stored at the biorepository will be identified only with the participant’s unique study identification (ID) number and the date the sample was obtained. Undoubtedly, there will be clear informed consent procedures, so participants understand the sample and DNA sharing process.
The sponsors noted in the press release that the study is being led by an academic steering committee chaired by Emma Guttman-Yassky, MD, PhD, The Sol and Clara Kest Professor of Dermatology and Immunology, and Vice Chair, Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York and Diamant Thaci, MD, PhD, Professor and Head Comprehensive Center for Inflammation Medicine, University of Lubeck, Germany.